QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors

References

• R.P. Iyer, N.L. Patterson, G.B. Fields, and M. Lindsey, The history of matrix metalloproteinases: Milestones, myths, and misperceptions, Am. J. Physiol. Heart Circ. Physiol. 303 (2012), pp. H919–H930.
   PubMed Web of Science ®Google Scholar
• X.S. Puente, L.M. Sanchez, C.M. Overall, and C. Lopez-Otin, Human and mouse proteases: A comparative genomic approach, Nat. Rev. Gen. 4 (2003), pp. 544–558.
   PubMed Web of Science ®Google Scholar
• C. Frantz, M. Kathleen, I. Stewart, and M. Valerie, Weaver, the extracellular matrix at a glance, J. Cell Sci. 123 (2010), pp. 4195–4200.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Pharmacol. Res. 122 (2017), pp. 8–19.
   Google Scholar
• E. Nuti, F. Casalini, S. Santamaria, P. Gabelloni, S. Bendinelli, E. Da Pozzo, B. Costa, L. Marinelli, V. La Pietra, E. Novellino, M.M. Bernardo, R. Fridman, F. Da Settim, C. Martini, and A. Rossello, Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors, Eur. J. Med. Chem. 46 (2011), pp. 2617–2629.
   Web of Science ®Google Scholar
• B. Fabre, K. Filipiak, J.M. Zapico, N. Díaz, R.J. Carbajo, A.K. Schott, M.P. Martínez-Alcázar, D. Suárez, A. Pineda-Lucena, A. Ramos, and B. de Pascual-Teresa, Progress towards water-soluble triazolebased selective MMP-2 inhibitors, Org. Biomol. Chem. 11 (2013), pp. 6623–6641.
   PubMed Web of Science ®Google Scholar
• E. Nuti, A.R. Cantelmo, C. Gallo, A. Bruno, B. Bassani, C. Camodeca, T. Tuccinardi, L. Vera, E. Orlandini, S. Nencetti, E.A. Stura, A. Martinelli, V. Dive, A. Albini, and A. Rossello, N-O-isopropyl sulpfonamido- based hydroxamates as matrix metalloproteinase inhibors: Hit selection and in vivo antiangiogenic activity, J. Med. Chem. 58 (2015), pp. 7224–7240.
   PubMed Web of Science ®Google Scholar
• J. Zhang, X. Li, Y. Jiang, J. Feng, X. Li, Y. Zhang, and W. Xu, Design, synthesis and preliminaryevaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors, Bioorg. Med. Chem. 22 (2014), pp. 3055–3064.
   Web of Science ®Google Scholar
• A.K. Halder, S. Mallick, D. Shikha, A. Saha, K. D. Saha, and T. Jha, Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity, RSC Adv. 5 (2015), pp. 72373–72386.
   Google Scholar
• I.H. Park and M.M Kim, Spermidine inhibits MMP-2 via modulation of histone acetyltransferase and histone deacetylase in HDFs, Int. J. Bio. Macromol. 51 (2012), pp. 1003–1007.
   PubMed Web of Science ®Google Scholar
• C. Tallant, A. Marrero, and F.X. Gomis-Rüth, Matrix metalloproteinases: Fold and function of their catalytic domains, Biochim. Biophys. Acta 1803 (2010), pp. 20–28.
   PubMed Web of Science ®Google Scholar
• A. Scozzafava and C.T. Supuran, Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes, J. Med. Chem. 43 (1997), pp. 3677–3687.
   Google Scholar
• N. Adhikari, A. Mukherjee, A. Saha, and T. Jha, Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview, Eur. J. Med. Chem. (2017), pp. 72–109.
   Web of Science ®Google Scholar
• I. Bertini, M. Fragai, A. Giachetti, C. Luchinat, M. Maletta, G. Parigi, and K.J. Yeo, Combining in silico tools and NMR data to validate protein-ligand structural models: Application to matrix metalloproteinases, J. Med. Chem. 48 (2005), pp. 7544–7559.
   Web of Science ®Google Scholar
• M. Aschi, N. Besker, N. Re, G.Pochetti, C. Coletti, C. Gallin, and F. Mazza, Stereoselectivity by enantiomeric inhibitors of matrix metalloproteinase-8: New insights from molecular dynamics simulations, J. Med. Chem. 50 (2007), pp. 211–218.
   Web of Science ®Google Scholar
• B.G. Rao, Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies, Curr. Pharm. Des. 11 (2005), pp. 295–322.
   Google Scholar
• A. Adhikari, S.A. Amin, A. Saha, and T. Jha, Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs, J. Mol. Struct. 1156 (2017), pp. 501–515.
   Web of Science ®Google Scholar
• R.J. Turner and F.R. Sharp, Implications of MMP-9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke, Front. Cell Neurosci. 10 (2016), p. 56.
   Google Scholar
• D. Kumar and S.P. Gupta, A quantitative structure–activity relationship study on some matrix metalloproteinase and collagenase inhibitors, Bioorg. Med. Chem. 11 (2002), pp. 421–426.
   Web of Science ®Google Scholar
• S.P. Gupta, D. Kumar, and S. Kumaran, A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from funtionalized 4-aminoprolines, Bioorg. Med. Chem. 11 (2003), pp. 1975–1981.
   Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors, J. Pharm. and Pharmacol. 65 (2013), pp. 1541–1554.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem. 24 (2016), pp. 4291–4309.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. 29 (2018), pp. 285–297.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Understanding chemico-biological interactions of glutamate MMP-2 inhibitors through rigorous alignment-dependent 3D-QSAR analyses, Chem. Select. 2 (2017), pp. 7888–7898.
   Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs, J. Mol. Struct. 1156 (2018), pp. 501–515.
   Web of Science ®Google Scholar
• T. Jha, N. Adhikari, A. Saha, and S.A. Amin, Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors, SAR QSAR Environ. Res. 29 (2018), pp. 43–68.
   Google Scholar
• A. Rossello, E. Nuti, E. Orlandini, P. Carelli, S. Rapposelli, M. Macchia, F. Minutolo, L. Carbonaro, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo, New N-arylsulfonyl-nalkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2), Bioorg. Med. Chem. Lett. 12 (2004), pp. 2441–2450.
   Google Scholar
• E. Nuti, E. Orladini, N. Susanna, A. Rossello, A. Innocenti, A. Scozzafava, and C. Supuran, Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor associated isozymes IX and cytosolic isozyme I and II with sulfonylatedhydroxamates, Bioorg. Med. Chem. 15 (2007), pp. 2298–2311.
   PubMed Web of Science ®Google Scholar
• E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli, N. Lim, R. Visse, H. Nagase, and A. Rossello, N-O-isopropyl sulfonamido- based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 as potential therapeutic agents for osteoarthritis, J. Med. Chem. 52 (2009), pp. 4757–4773.
   Web of Science ®Google Scholar
• E. Nuti, F. Casalini, S. Santamaria, M. Fabbi, G. Carbotti, S.Ferrini, and A. Rosello. Selective arylsulfonamide inhibitors of ADAM-17: Hit optimization and activity in ovarian cancer cell models, J. Med. Chem. 56 (2013), pp. 8089–8103.
   Google Scholar
• S. Sjøli, E. Nuti, E. Camodeca, I. Bilto, A. Rossello, J.O. Winberg, and O.A. Adekoya, Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors, Eur. J. Med. Chem. 108 (2016), pp. 141–153.
   Google Scholar
• C.W. Yap, PaDEL-Descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474.
   Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, Insight into the structural requirements of theophylline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors through multi-QSAR modelling and molecular docking approaches, Curr. Drug. Des. Technol. 13 (2016), pp. 84–100.
   PubMedGoogle Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64.
   Google Scholar
• QSAR tools, DTC laboratory, India, 2015; Software available at https://dtclab.webs.com/software-tools. (accessed on 22nd September 2018).
   Google Scholar
• P. Ambure, R.B. Aher, A. Gajewicz, T. Puzyn, and K. Roy, “NanoBRIDGES” software: Open access tools to perform QSAR and nano-QSAR modeling, Chemom. Intell. Lab. Syst. 147 (2015), pp. 1–13.
   Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development, Principles for the validation, for regulatory purposes, of (quantitative) structure-activity relationship models. Available at https://www.oecd.org/chemicalsafety/risk-assessment/37849783.pdf.
   Google Scholar
• K. Roy, S. Kar, and R.N. Das, Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment, Academic Press, London, UK, 2015.
   Google Scholar
• A. Golbraikh and A. Tropsha, Predictive QSAR modelling based on diversity sampling of experimental datasets for the training and test set selection, J. Comput. Aided Mol. Des. 16 (2002), pp. 357–369.
   PubMed Web of Science ®Google Scholar
• P.A.P. Moran, Notes on continuous stochastic phenomena, Biometrika 37 (1950), pp. 17–23.
   PubMed Web of Science ®Google Scholar
• R. Todechini and V. Consonni, Molecular Descriptors for Chemoinformatics, Vol.1, Wiley-VCH, Weiheim, Germany, 2009.
   Google Scholar
• R.C. Geary, The contiguity ratio and statistical mapping, Incorp. Stat. 5 (1954), pp. 115–145.
   Google Scholar
• G. Moreau and P. Broto, Autocorrelation of molecular structures. Application to SAR studies, Nouv. J. Chim. 4 (1980), pp. 757–764.
   Google Scholar